* 43-44 pct of patients show no disease activity after 2 yrs
* Merck's cladribine leading race to be first oral MS drug
* German drugmaker's shares up 2 pct
(Adds details, shares, background)
LONDON, Sept 11 (Reuters) - A new analysis of data from a clinical trial of Merck KGaA's (MRCG.DE) oral drug cladribine has underscored its potential as a treatment for multiple sclerosis, researchers said on Friday.
The fresh finding from the Phase III trial -- headline results of which were first presented in April -- showed a short course of cladribine tablets significantly increased the proportion of patients without disease activity after two years.
Research presented at the European Committee for Treatment and Research in Multiple Sclerosis congress in Duesseldorf found 43 and 44 percent of patients treated with two different doses of cladribine had absence of disease activity, compared with 16 percent of those on placebo.
============================================
0 comments:
Post a Comment